Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 20/20 | 0.77 |
| ▸ | TYK2 | P29597 | 19/20 | 0.77 |
| ▸ | JAK1 | P23458 | 14/20 | 0.77 |
| ▸ | JAK2 | O60674 | 13/20 | 0.77 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.57 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24690098 | 1.00 | JAK3 (0.77) | JAK3TYK2JAK1JAK2P2RX3 | |
| SCHEMBL25594366 | 1.00 | JAK3 (0.77) | JAK3TYK2JAK1JAK2P2RX3 | |
| SCHEMBL24336999 | 1.00 | JAK3 (0.77) | JAK3TYK2JAK1JAK2P2RX3 | |
| SCHEMBL24337135 | 0.95 | JAK3 (0.81) | JAK3TYK2JAK1JAK2P2RX3 | |
| SCHEMBL21229884 | 0.95 | JAK3 (0.81) | JAK3TYK2JAK1JAK2P2RX3 | |
| SCHEMBL22055332 | 0.89 | JAK3 (0.71) | JAK3TYK2JAK1JAK2P2RX3 | |
| SCHEMBL22054495 | 0.89 | JAK3 (0.70) | JAK3TYK2JAK1JAK2P2RX3 | |
| SCHEMBL22055305 | 0.88 | JAK3 (0.69) | JAK3TYK2JAK1JAK2P2RX3 | |
| SCHEMBL24995517 | 0.88 | JAK3 (0.92) | JAK3TYK2JAK1JAK2P2RX3 | |
| SCHEMBL23878812 | 0.88 | JAK3 (0.92) | JAK3TYK2JAK1JAK2P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739103-B2 | Processes for preparing a pan-JAK inhibitor and related intermediate compounds | Theravance Biopharma R&D LP, LLC (US) | 2023-08-29 | — | — | US | disclosed |
| US-20220112219-A1 | PROCESSES FOR PREPARING A PAN-JAK INHIBITOR AND RELATED INTERMEDIATE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112219-A1 | PROCESSES FOR PREPARING A PAN-JAK INHIBITOR AND RELATED INTERMEDIATE COMPOUNDS | JAK1, JAK3, JAK2 | JAK3 2/4885TYK2 50/4885JAK1 1/4885 |
| US-11739103-B2 | Processes for preparing a pan-JAK inhibitor and related intermediate compounds | JAK1, JAK3, JAK2 | JAK3 2/4885TYK2 50/4885JAK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.